AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.

AB Science S.A.

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform is designed and developed to optimize the performance of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes bi-hormonal products, which include BioChaperone AsPram, which is a combination of rapid insulin aspart with pramlintide; and BioChaperone Glargine Liraglutidea, which is a fixed combination of insulin glargine with an analogue of the GLP-1 receptor. In addition, the company's preclinical pipeline includes multihormonal products for the treatment of obesity, including BioChaperone GluExe, which is a combination of glucagon and exenatide; PramExe, which is a combination of pramlintide and exenatide; and BioChaperone PramGluExe, which is a triple combination of pramlintide, glucagon and exenatide. It has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. The company was incorporated in 2005 and is headquartered in Lyon, France.

Adocia SA

Poxel SA is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, focusing on non-alcoholic steatohepatitis (NASH) and rare disorders.

Poxel SA

AB Science develops compounds for therapeutic use in various diseases, including neurodegenerative disorders, oncology, inflammatory diseases, and viral diseases. The company is self-described as having breakthrough mechanisms of action in its products.

Metric
Company Name	AB Science S.A.	Adocia SA	Poxel SA
Symbol	AB	ADOC
MSH ID	COM:AB-SCIENCE	COM:ADOCIA	COM:POXEL
Market	STOCKS	STOCKS	PRIVATE
Sector	Healthcare	Healthcare	Healthcare & Health Services
Industry	Drug Manufacturers - Specialty & Generic	Biotechnology	Biotechnology
Country	FR	FR	FR
Stage		Post-IPO Debt	Post-IPO Debt
Employee Count	51	78
Website	ab-science.com	adocia.com	poxel.com
LinkedIn		adocia	poxel
Founders

Metric
Market Cap	61.06M	100.30M
Enterprise Value
Monthly Web Traffic	690	521	4.88K
Web Traffic Growth	-0.89	-0.54	-0.63
Valuation
Raised Capital		6.96M	50M

Metric
Revenue	1.02M	2.27M
Revenue (LTM)
Revenue (NTM)
Gross Profit	620.01K	-18.95M
EBITDA	-5.77M	-18.09M
Operating Income	-14.18M	-18.61M
Net Income	-10.61M	-22.35M
EPS	-0.21	-2.02
Diluted EPS	-0.16	-2.02
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-0.30	-2.44
Operating Profit Margin	-13.13	-2.49
EBITDA Margin	-5.64	-7.96
Net Profit Margin	-8.80	-2.76
Return on Equity	0.91	3.60
Return on Assets	-0.42	-1.08
Return on Capital Employed	-1.68	4.03

COM:AB-SCIENCE

AB Science

Last Close

0.80

25/11 08:59

Market Cap

57.80M

Beta: -

Volume Today

5.88K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-10.63	-11.60
P/B Ratio	-4.06	-6.17
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	167.28	35.40
EV Multiple	-1.78	-2.91

Metric
Days Sales Outstanding		275.72
Days Payables Outstanding	86.68K	745.68
Days Inventory Outstanding	95.78	9.81
Operating Cycle	7.34K	823.59
Cash Conversion Cycle	5.56K	776.31
Asset Turnover	0.07	0.53

Metric
Operating Cash Flow	-17.82M	-5.23M
Free Cash Flow	-18.18M	-5.39M
Cash Flow to Debt	-0.89	-0.46
Operating Cash Flow/Sales	-8.90	-1.27
Free Cash Flow Yield	-0.12	-0.11

Metric
Cash & Equivalents	6.41M	13.69M
Accounts Receivable		1.23M
Inventory	354.89K	287.29K
Goodwill
Debt to Capitalization	135.44	2.81
Debt to Assets	1.00	1.08
Current Ratio	0.90	1.05
Quick Ratio	1.41	1.01

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.14
R&D to Revenue	13.93
SG&A to Revenue	1.95